Fabrice Agou

Fabrice Agou serves as Head of Facility at the Chemogenomic and Biological Screening Platform (PF-CCB) within the Technology Department at Institut Pasteur in Paris, France. His leadership encompasses overseeing high-throughput screening operations that support drug discovery and biological research across the institution.

Dr. Agou's research spans multiple interdisciplinary fields with a strong emphasis on screening technologies. His work integrates cell biology, virology, and drug discovery methodologies to address complex biological questions. His laboratory specializes in developing and implementing robust bioassays compatible with high-throughput and high-content screening standards, from assay optimization to miniaturization and automation. The platform under his leadership supports both target-based (HTS) and phenotypic (HCS) screening approaches to identify active chemical substances and genetic modulators of function.

Analysis of Dr. Agou's recent publications reveals a strong research trajectory focused on viral pathogens (particularly SARS-CoV-2), cell division mechanisms, and stem cell applications in screening. His work demonstrates expertise in multiple screening modalities and has resulted in significant contributions to understanding viral entry mechanisms, cytokinesis regulation, and drug discovery pipelines. The research spans both basic science investigations and translational applications with therapeutic potential.

Under Dr. Agou's leadership, the PF-CCB platform supports numerous research teams through assay development, screening campaigns, and hit validation. The facility maintains extensive chemical and biological libraries including FDA-approved compounds, target-selective libraries, and specialized collections for various disease areas. The platform's technological capabilities include advanced microscopy systems, liquid handling equipment, and biophysical detection instruments that enable comprehensive screening approaches.